Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 14/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.36 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.36 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.36 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17601479 | 1.00 | IDH1 (0.51) | IDH1ALDH1A1TDP1GRIN2DGRIN3B | |
| SCHEMBL30064586 | 1.00 | IDH1 (0.51) | IDH1ALDH1A1TDP1GRIN2DGRIN3B | |
| SCHEMBL30064579 | 1.00 | IDH1 (0.51) | IDH1ALDH1A1TDP1GRIN2DGRIN3B | |
| SCHEMBL17601292 | 1.00 | IDH1 (0.51) | IDH1ALDH1A1TDP1GRIN2DGRIN3B | |
| SCHEMBL30064718 | 1.00 | IDH1 (0.51) | IDH1ALDH1A1TDP1GRIN2DGRIN3B | |
| Hydrochloric Acid SCHEMBL17601370 | 0.99 | IDH1 (0.50) | IDH1ALDH1A1TDP1GRIN2DGRIN3B | |
| Hydrochloric Acid SCHEMBL30623298 | 0.99 | IDH1 (0.50) | IDH1ALDH1A1TDP1GRIN2DGRIN3B | |
| Hydrochloric Acid SCHEMBL17601511 | 0.99 | IDH1 (0.50) | IDH1ALDH1A1TDP1GRIN2DGRIN3B | |
| Hydrochloric Acid SCHEMBL30065248 | 0.99 | IDH1 (0.50) | IDH1ALDH1A1TDP1GRIN2DGRIN3B | |
| SCHEMBL21549755 | 0.88 | IDH1 (0.53) | IDH1ALDH1A1TDP1GRIN2DGRIN3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12275715-B2 | Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors | FORMA THERAPEUTICS, INC. (US) | 2025-04-15 | — | — | US | disclosed |
| US-20240150319-A1 | PYRIDIN-2(1H)-ONE QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2024-05-09 | — | — | US | disclosed |
| CN-117695280-A | Pyridin-2 (1H) -one quinolinone derivatives as mutant isocitrate dehydrogenase inhibitors | 福马治疗股份有限公司 | 2024-03-15 | — | — | CN | disclosed |
| CN-111909130-B | Pyridin-2 (1H) -one quinolinone derivatives as mutant isocitrate dehydrogenase inhibitors | 福马治疗股份有限公司 | 2023-10-31 | — | — | CN | disclosed |
| EP-4257131-A2 | PYRIDIN-2(1H)-ONE QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | Forma Therapeutics, Inc. (US) | 2023-10-11 | — | — | EP | disclosed |
| EP-4257131-A2 | PYRIDIN-2(1H)-ONE QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | Forma Therapeutics, Inc. (US) | 2023-10-11 | — | — | EP | disclosed |
| EP-3733662-B1 | PYRIDIN-2(1H)-ONE QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS INC (US) | 2023-06-07 | — | — | EP | disclosed |
| EP-3733662-B1 | PYRIDIN-2(1H)-ONE QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20230125739-A1 | PYRIDIN-2(1H)-ONE QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | US | disclosed |
| US-20230125739-A1 | PYRIDIN-2(1H)-ONE QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | US | disclosed |
| WO-2016044789-A1 | PYRIDIN-2(1H)-ONE QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2016-03-24 | — | — | WO | disclosed |
| WO-2016044789-A1 | PYRIDIN-2(1H)-ONE QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2016-03-24 | — | — | WO | disclosed |
| WO-2016044787-A1 | PYRIDINYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2016-03-24 | — | — | WO | disclosed |
| WO-2016044787-A1 | PYRIDINYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2016-03-24 | — | — | WO | disclosed |
| WO-2016044781-A1 | QUINOLINONE PYRIMIDINES COMPOSITIONS AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2016-03-24 | — | — | WO | disclosed |
| US-20160083367-A1 | PYRIDINYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. | 2016-03-24 | — | — | US | disclosed |
| US-20160083367-A1 | PYRIDINYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. | 2016-03-24 | — | — | US | disclosed |
| US-20160083367-A1 | PYRIDINYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. | 2016-03-24 | — | — | US | disclosed |
| US-20160083365-A1 | QUINOLINONE PYRIMIDINES COMPOSITIONS AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. | 2016-03-24 | — | — | US | disclosed |
| US-20160083365-A1 | QUINOLINONE PYRIMIDINES COMPOSITIONS AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. | 2016-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230125739-A1 | PYRIDIN-2(1H)-ONE QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | IDH1, IDH3A, IDH2 | IDH1 1/4885ALDH1A1 314/4885TDP1 405/4885 |
| US-12275715-B2 | Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors | IDH1, IDH3A, IDH2 | IDH1 1/4885ALDH1A1 314/4885TDP1 405/4885 |
| US-20160083367-A1 | PYRIDINYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | IDH1, IDH3A, IDH3B | IDH1 1/4885ALDH1A1 803/4885TDP1 638/4885 |
| US-20240150319-A1 | PYRIDIN-2(1H)-ONE QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | IDH1, IDH3A, IDH2 | IDH1 1/4885ALDH1A1 314/4885TDP1 405/4885 |
| US-20160083365-A1 | QUINOLINONE PYRIMIDINES COMPOSITIONS AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | IDH1, IDH3A, IDH3B | IDH1 1/4885ALDH1A1 604/4885TDP1 299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.